These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 456557)

  • 1. Carcinogenicity of carteolol hydrochloride in Balb/c mice.
    Kurosumi M; Hatori M; Nishino H
    Farmaco Prat; 1979 May; 34(5):202-9. PubMed ID: 456557
    [No Abstract]   [Full Text] [Related]  

  • 2. Reproduction study of carteolol hydrochloride in mice. Part 2. Peri -and postnatal toxicity.
    Tamagawa M; Numoto T; Tanaka N; Nishino H
    J Toxicol Sci; 1979 Feb; 4(1):59-77. PubMed ID: 480406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toxicology of carteolol].
    Lang W
    Arzneimittelforschung; 1983; 33(2a):290-6. PubMed ID: 6682320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ocular toxicity of two beta blocking drugs, carteolol and practolol, in beagle dogs.
    Tanaka N; Ohkawa T; Hiyama T; Nakajima A
    J Pharmacol Exp Ther; 1983 Feb; 224(2):424-30. PubMed ID: 6822964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the opacifying effects of carteolol.HCl and 8-hydroxycarteolol.HCl in the isolated porcine cornea.
    Igarashi H; Katsuta Y; Sawa K; Nakazato Y; Kawasaki T
    Fundam Appl Toxicol; 1990 Apr; 14(3):554-9. PubMed ID: 2340982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thresholds of carcinogenicity in the ED01 study.
    Andersen ME; Conolly RB; Gaylor DW
    Toxicol Sci; 2003 Aug; 74(2):486-7; author reply 487-8. PubMed ID: 12874369
    [No Abstract]   [Full Text] [Related]  

  • 7. A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity.
    Faccini JM; Irisarri E; Monro AM
    Toxicology; 1981; 21(4):279-90. PubMed ID: 6117955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study.
    Crump KS; Clewell HJ
    Toxicol Sci; 2003 Aug; 74(2):485; author reply 485-6. PubMed ID: 12730607
    [No Abstract]   [Full Text] [Related]  

  • 9. Derivatives of 2-N-arylalkylamino-2-methyl-1-propanol with antiarrhythmic activity.
    Eckstein M; Zajaczkowska J; Krupińska J; Michna M
    Pol J Pharmacol Pharm; 1986; 38(2):215-20. PubMed ID: 3748893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-carcinogenicity in mice of a sulfonic acid derivative of 2-naphthylamine.
    Della Porta G; Dragani TA
    Carcinogenesis; 1982; 3(6):647-9. PubMed ID: 7116558
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumorigenicity test of 1,3- and 1,8-dinitropyrene in BALB/c mice.
    Otofuji T; Horikawa K; Maeda T; Sano N; Izumi K; Otsuka H; Tokiwa H
    J Natl Cancer Inst; 1987 Jul; 79(1):185-8. PubMed ID: 3037147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The abnormal ECG and the appearance of methacholine-induced arrhythmias in SART mice and effects of beta-blockers, oxprenolol, propranolol, and carteolol].
    Hata T; Kita T; Itoh E; Harada N
    Nihon Yakurigaku Zasshi; 1984 May; 83(5):413-24. PubMed ID: 6381261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,6-Dinitropyrene: mutagenicity in Salmonella and carcinogenicity in BALB/c mice.
    Tokiwa H; Otofuji T; Horikawa K; Kitamori S; Otsuka H; Manabe Y; Kinouchi T; Ohnishi Y
    J Natl Cancer Inst; 1984 Dec; 73(6):1359-63. PubMed ID: 6392672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a non-human primate model of drug-induced torsades de pointes.
    Beatch GN; Davis DR; Dickenson DR; Adaikan PG; Hayes E; Rhamberg M; Walker MJ
    Proc West Pharmacol Soc; 1997; 40():13-6. PubMed ID: 9436200
    [No Abstract]   [Full Text] [Related]  

  • 15. Carcinogenicity of substituted-benzenediamines (phenylenediamines) in rats and mice.
    Sontag JM
    J Natl Cancer Inst; 1981 Mar; 66(3):591-602. PubMed ID: 6937712
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rifampicin in a carcinogenic experiment (author's transl)].
    Bichel J
    Folia Clin Int (Barc); 1974 Oct; 24(10):708-11. PubMed ID: 4430390
    [No Abstract]   [Full Text] [Related]  

  • 17. [Blastomogenic effects of some azo-containing compounds on the progeny of test mice].
    Golub' NI; Kolesnichenko TS; Shabad LM
    Biull Eksp Biol Med; 1974 Dec; 78(12):62-5. PubMed ID: 4216379
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical experiences with carteolol in patients with essential hypertension].
    Viehmann P
    Arzneimittelforschung; 1983; 33(2a):322-5. PubMed ID: 6340701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of a new beta-blocking agent (1-isopropylamino-3-(2-methyl-3-nitrophenoxy)-propan-2-ol).
    Michalska Z; Robak J; Kostka-Trabka E; Grodzińska L; Górka Z; Gryglewski R
    Folia Biol (Krakow); 1974; 22(2):217-28. PubMed ID: 4151603
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antiarrhythmic action of beta-blocking agent in patients with mitral valve prolapse having premature ventricular contractions].
    Shioto T; Takenaka K; Sakamoto T; Amano K; Suzuki J; Amano W; Takahashi H; Sugimoto T
    J Cardiol Suppl; 1989; 21():65-72, discussion 73-4. PubMed ID: 2476544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.